Search results
Results From The WOW.Com Content Network
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...
The FTC sued the three PBMs in September, accusing them of steering diabetes patients toward higher priced insulin products in order to reap millions of dollars in rebates from drugmakers.
Prior FTC inquiry. Friday’s action comes a little more than two months after the FTC published a scathing interim report on the PBM industry that followed a two-year inquiry. It detailed how ...
On Tuesday, the FTC issued an interim report, saying the three biggest middlemen - managing 79% of U.S. prescription drug claims - have used years of dealmaking to gain outsized influence on drug ...
Importantly, all five FTC commissioners signed off on the release of the report. This includes Andrew Ferguson, Khan’s designated replacement under Trump, as well as his fellow Republican ...
The company offered to settle, but the FTC declined. In January 2020, Axon filed a lawsuit in the United States District Court for the District of Arizona, challenging the constitutionality of FTC's structure. The district court dismissed the case, holding that federal law stripped it of jurisdiction to consider constitutional claims against ...
The lawsuit asks a federal judge in St. Louis, Missouri to order the FTC to take the report down and recuse Chair Lina Khan from any actions pertaining to the company, which is owned by Cigna Corp.
"The FTC's interim report lays out how dominant pharmacy benefit managers can hike the cost of drugs — including overcharging patients for cancer drugs," FTC Chair Lina Khan said in a statement.